-
Galderma Laboratories LP et al. v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:17-cv-01783
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/11/2017
- Closed: 03/12/2020
- Latest Docket Entry: 11/17/2020
- PACER
3
Plaintiffs
2
Defendants
1
Accused
Product
6
Patents-in-Suit
1,057
Days in
Litigation
-
Galderma Laboratories LP et al. v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:17-cv-01783
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/11/2017
- Closed: 03/12/2020
- Latest Docket Entry: 11/17/2020
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 12 |
The method of claim 11, wherein the pharmaceutical composition comprises about 1% by weight ivermectin.
|
Invalid
Entry 260 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 6 |
A method of treating inflammatory lesions of papulopustular rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the inflammatory lesions of papulopustular rosacea a pharmaceutical
view more
|
Invalid
Entry 260 |
| 7 |
The method of claim 6, wherein as early as 2 weeks after the initial administration of the pharmaceutical composition, the significant reduction in inflammatory lesion count is observed.
|
Invalid
Entry 260 |
| 10 |
The method of claim 8, wherein the once daily topical administration to the subject the pharmaceutical composition results in more reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the
view more
|
Invalid
Entry 260 |
| 11 |
The method of claim 8, wherein the once daily topical administration to the subject the pharmaceutical composition results in longer relapse-free time of the inflammatory lesions in the subject in comparison to that achieved by topically
view more
|
Invalid
Entry 260 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The method of claim 1, wherein the treatment results in more reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising
view more
|
Invalid
Entry 260 |
| 3 |
The method of claim 1, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by twice daily topically administering to the subject a second pharmaceutical
view more
|
Invalid
Entry 260 |
| 6 |
The method of claim 5, wherein the subject has 15 or more of the inflammatory lesions before the treatment.
|
Invalid
Entry 260 |
-
Infringement
Teva Pharmaceuticals USA, Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 1% generic version of Soolantra ivermectin Cream | US 9,089,587 B2 |
12
|
No infringement
Entry 260
|
| 1% generic version of Soolantra ivermectin Cream | US 9,233,117 B2 |
2, 3, 6
|
No infringement
Entry 260
|
| 1% generic version of Soolantra ivermectin Cream | US 9,233,118 B2 |
6, 7, 10, 11
|
No infringement
Entry 260
|